Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $396.00 price target on BeOne Medicines (NASDAQ: ONC).

The analyst commented, "We reiterate our Market Outperform rating and PT of $396 based on a discounted EPS and revenue multiple analysis on BeOne Medicines. At AACR, BeOne had six presentations, including one on its PRMT5 inhibitor (PRMT5i), BGB-58067, showing a superior in vitro and in vivo preclinical profile vs. four competitors. With Brukinsa on track to generate ~$5B+ in 2026, an industry-leading development pipeline, with U.S. and EU sonrotoclax approvals on the way, and a strong cash position of $4.6B, we believe BeOne shares represent an attractive investment opportunity, especially given the recent weakness in shares."

For an analyst ratings summary and ratings history on BeOne Medicines click here. For more ratings news on BeOne Medicines click here.

Shares of BeOne Medicines closed at $323.87 yesterday.